The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation

被引:169
作者
Gelman, Andrew E.
LaRosa, David F.
Zhang, Jidong
Walsh, Patrick T.
Choi, Yongwon
Sunyer, J. Oriol
Turka, Laurence A. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19010 USA
[2] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19010 USA
[3] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/j.immuni.2006.08.023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
While T cells respond directly to toll-like receptor (TLR) agonists, TLR-signaling pathways in T cells are poorly characterized. Here we demonstrate in CD4(+) T cells that CpG DNA directly enhances proliferation, prevents anergy, and augments humoral responses to a T cell-dependent antigen by a Myeloid differentiation primary-response protein 88 (MyD88) and Phosphatidylinositol 3-kinase (PI-3 kinase)-dependent pathway. PI-3 kinase activation required a putative Src-homology domain (SH2) binding motif in the MyD88 Toll-Like or IL-1 Receptor (TIR) domain. Reconstitution of MyD88-deficient primary T cells with a MyD88 transgene mutated in this motif abrogated association of PI-3 kinase with MyD88, phosphorylation of protein kinase B (Akt) and Glycogen Synthetase Kinase-3 (GSK-3), and interleukin-2 (IL-2) production. The MyD88 death domain, on the other hand, was required for NF-kB activation and survival. These studies identify a MyD88-dependent PI-3 kinase-signaling pathway in T cells that differentiates CpG DNA-mediated proliferation from survival and is required for an in vivo T cell-dependent immune response.
引用
收藏
页码:783 / 793
页数:11
相关论文
共 43 条
[1]   Role of adapters in Toll-like receptor signalling [J].
Akira, S ;
Yamamoto, M ;
Takeda, K .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 :637-642
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]   Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3 [J].
Beals, CR ;
Sheridan, CM ;
Turck, CW ;
Gardner, P ;
Crabtree, GR .
SCIENCE, 1997, 275 (5308) :1930-1933
[4]  
Bendigs S, 1999, EUR J IMMUNOL, V29, P1209, DOI 10.1002/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO
[5]  
2-J
[6]   Cutting edge:: Distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL [J].
Burr, JS ;
Savage, NDL ;
Messah, GE ;
Kimzey, SL ;
Shaw, AS ;
Arch, RH ;
Green, JM .
JOURNAL OF IMMUNOLOGY, 2001, 166 (09) :5331-5335
[7]   Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide [J].
Caramalho, I ;
Lopes-Carvalho, T ;
Ostler, D ;
Zelenay, S ;
Haury, M ;
Demengeot, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (04) :403-411
[8]   Direct stimulation of human T cells via TLR5 and TLR7/8:: Flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells [J].
Caron, G ;
Duluc, D ;
Frémaux, I ;
Jeannin, P ;
David, C ;
Gascan, H ;
Delneste, Y .
JOURNAL OF IMMUNOLOGY, 2005, 175 (03) :1551-1557
[9]   The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL [J].
Chen, CL ;
Edelstein, LC ;
Gélinas, C .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2687-2695
[10]   Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus [J].
Christensen, SR ;
Kashgarian, M ;
Alexopoulou, L ;
Flavell, RA ;
Akira, S ;
Shlomchik, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (02) :321-331